nach oben

Erschienen in:

01.12.2016 | Review Article

Metabolomics in pancreatic cancer biomarkers research

verfasst von: Jaroslav Tumas, Kotryna Kvederaviciute, Marius Petrulionis, Benediktas Kurlinkus, Arnas Rimkus, Greta Sakalauskaite, Jonas Cicenas, Audrius Sileikis

Erschienen in: Medical Oncology | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Pancreatic cancer is one of the worst prognoses of all malignancies. More than 40,000 deaths a year from this disease are observed in European Union alone. The only possibly curative treatment of pancreatic cancer is surgery, yet only 15–20% of patients have operable disease and even patients, which go through surgery and adjuvant chemotherapy, survival is less than 30%. The sensitive and specific biomarkers which could be used for the advance of early diagnostics are needed and constantly researched. Metabolomics is a technology which analyzes the concentrations of low-molecular-weight metabolites (the metabolome) has lately effectively developed due to the improvements in analytical technology. Metabolome analysis can be a one of the useful approaches for the biomarker discovery and disease diagnosis. Here we discuss recent discoveries in the field of pancreatic cancer metabolomics as well as the most promising biomarkers for diagnostics, prognosis and prediction.

Duell EJ, Lucenteforte E, Olson SH, Bracci PM, Li D, Risch HA, et al. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol. 2012;23(11):2964–70. doi:10.1093/annonc/mds140.CrossRefPubMedPubMedCentral

Malvezzi M, Carioli G, Bertuccio P, Rosso T, Boffetta P, Levi F, et al. European cancer mortality predictions for the year 2016 with focus on leukaemias. Ann Oncol. 2016;27(4):725–31. doi:10.1093/annonc/mdw022.CrossRefPubMed

Carrato A, Falcone A, Ducreux M, Valle JW, Parnaby A, Djazouli K, et al. A systematic review of the burden of pancreatic cancer in Europe: real-world impact on survival, quality of life and costs. J Gastrointest Cancer. 2015;46(3):201–11. doi:10.1007/s12029-015-9724-1.CrossRefPubMedPubMedCentral

Šileikis A, Kurlinkus B, Kryžauskas M, Strupas K. Stage II pancreatic cancer: radical, palliative surgery or stenting? Surg Sci. 2015;6(12):555–61. doi:10.4236/ss.2015.612079.CrossRef

http://www.cancer.org/cancer/pancreaticcancer/detailedguide/pancreatic-cancer-diagnosis.

Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goere D, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v56–68. doi:10.1093/annonc/mdv295.CrossRefPubMed

Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467(7319):1114–7. doi:10.1038/nature09515.CrossRefPubMedPubMedCentral

Rochfort S. Metabolomics reviewed: a new “omics” platform technology for systems biology and implications for natural products research. J Nat Prod. 2005;68(12):1813–20. doi:10.1021/np050255w.CrossRefPubMed

Farshidfar F, Weljie AM, Kopciuk KA, Hilsden R, McGregor SE, Buie WD, et al. A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics. Br J Cancer. 2016;. doi:10.1038/bjc.2016.243.PubMed

10.

Budczies J, Denkert C. Tissue-based metabolomics to analyze the breast cancer metabolome. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer. 2016;207:157–75. doi:10.1007/978-3-319-42118-6_7.PubMed

11.

Yang J, Xu G, Zheng Y, Kong H, Pang T, Lv S, et al. Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases. J Chromatogr B Anal Technol Biomed Life Sci. 2004;813(1–2):59–65. doi:10.1016/j.jchromb.2004.09.032.CrossRef

12.

Zhang X, Zhu X, Wang C, Zhang H, Cai Z. Non-targeted and targeted metabolomics approaches to diagnosing lung cancer and predicting patient prognosis. Oncotarget. 2016;. doi:10.18632/oncotarget.11521.

13.

Odunsi K, Wollman RM, Ambrosone CB, Hutson A, McCann SE, Tammela J, et al. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int J Cancer. 2005;113(5):782–8. doi:10.1002/ijc.20651.CrossRefPubMed

14.

Lima AR, Bastos Mde L, Carvalho M, Guedes de Pinho P. Biomarker discovery in human prostate cancer: an update in metabolomics studies. Transl Oncol. 2016;9(4):357–70. doi:10.1016/j.tranon.2016.05.004.CrossRefPubMedPubMedCentral

15.

Agarwal A, Saif MW. KRAS in pancreatic cancer. JOP J Pancreas. 2014;15(4):303–5. doi:10.6092/1590-8577/2660.

16.

Hori Y, Miyabe K, Yoshida M, Nakazawa T, Hayashi K, Naitoh I, et al. Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma. PLoS ONE. 2015;10(3):e0118829. doi:10.1371/journal.pone.0118829.CrossRefPubMedPubMedCentral

17.

Fullerton PT Jr, Creighton CJ, Matzuk MM. Insights into SMAD4 loss in pancreatic cancer from inducible restoration of TGF-beta signaling. Mol Endocrinol. 2015;29(10):1440–53. doi:10.1210/me.2015-1102.CrossRefPubMedPubMedCentral

18.

McWilliams RR, Wieben ED, Rabe KG, Pedersen KS, Wu Y, Sicotte H, et al. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling. Eur J Hum Genet EJHG. 2011;19(4):472–8. doi:10.1038/ejhg.2010.198.CrossRefPubMed

19.

Cicenas J, Cicenas E. Multi-kinase inhibitors, AURKs and cancer. Med Oncol. 2016;33(5):43. doi:10.1007/s12032-016-0758-4.CrossRefPubMed

20.

Henke RT, Haddad BR, Kim SE, Rone JD, Mani A, Jessup JM, et al. Overexpression of the nuclear receptor coactivator AIB1 (SRC-3) during progression of pancreatic adenocarcinoma. Clin Cancer Res. 2004;10(18 Pt 1):6134–42. doi:10.1158/1078-0432.CCR-04-0561.CrossRefPubMed

21.

Cicenas J. The potential role of Akt phosphorylation in human cancers. Int J Biol Mark. 2008;23(1):1–9.

22.

Cicenas J, Urban P, Vuaroqueaux V, Labuhn M, Kung W, Wight E, et al. Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. Breast Cancer Res BCR. 2005;7(4):R394–401. doi:10.1186/bcr1015.CrossRefPubMed

23.

Ueda S, Ogata S, Tsuda H, Kawarabayashi N, Kimura M, Sugiura Y, et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas. 2004;29(1):e1–8.CrossRefPubMed

24.

Audrius S, Marius P, Benediktas K, Marija G, Algirdas K, Jonas C, et al. Current role of proteomics in pancreatic cancer biomarkers research. Curr Proteomics. 2016;13(1):68–75. doi:10.2174/1570164613666160413130201.CrossRef

25.

Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013;496(7443):101–5. doi:10.1038/nature12040.CrossRefPubMedPubMedCentral

26.

Rosenfeldt MT, O’Prey J, Morton JP, Nixon C, MacKay G, Mrowinska A, et al. p53 status determines the role of autophagy in pancreatic tumour development. Nature. 2013;504(7479):296–300. doi:10.1038/nature12865.CrossRefPubMed

27.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi:10.1016/j.cell.2011.02.013.CrossRefPubMed

28.

Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012;21(3):297–308. doi:10.1016/j.ccr.2012.02.014.CrossRefPubMedPubMedCentral

29.

Yu M, Zhou Q, Zhou Y, Fu Z, Tan L, Ye X, et al. Metabolic phenotypes in pancreatic cancer. PLoS ONE. 2015;10(2):e0115153. doi:10.1371/journal.pone.0115153.CrossRefPubMedPubMedCentral

30.

Xiang J, Liu L, Wang W, Xu H, Wu C, Xu J, et al. Metabolic tumor burden: a new promising way to reach precise personalized therapy in PDAC. Cancer Lett. 2015;359(2):165–8. doi:10.1016/j.canlet.2015.01.023.CrossRefPubMed

31.

Urayama S. Pancreatic cancer early detection: expanding higher-risk group with clinical and metabolomics parameters. World J Gastroenterol. 2015;21(6):1707–17. doi:10.3748/wjg.v21.i6.1707.CrossRefPubMedPubMedCentral

32.

Yoshida M, Nishiumi S, Azuma T. Gastroenterological cancer diagnosis by metabolomics-discovery of pancreatic cancer biomarker. Rinsho byori Japan J Clin Pathol. 2015;63(4):450–6.

33.

Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metab Off J Metab Soc. 2010;6(1):78–95. doi:10.1007/s11306-009-0178-y.

34.

Bathe OF, Shaykhutdinov R, Kopciuk K, Weljie AM, McKay A, Sutherland FR, et al. Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiol Biomark Prev. 2011;20(1):140–7. doi:10.1158/1055-9965.EPI-10-0712.CrossRef

35.

Spratlin JL, Pitts TM, Kulikowski GN, Morelli MP, Tentler JJ, Serkova NJ, et al. Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines. Anticancer Res. 2011;31(4):1093–103.PubMedPubMedCentral

36.

Napoli C, Sperandio N, Lawlor RT, Scarpa A, Molinari H, Assfalg M. Urine metabolic signature of pancreatic ductal adenocarcinoma by (1)h nuclear magnetic resonance: identification, mapping, and evolution. J Proteome Res. 2012;11(2):1274–83. doi:10.1021/pr200960u.CrossRefPubMed

37.

Tesiram YA, Lerner M, Stewart C, Njoku C, Brackett DJ. Utility of nuclear magnetic resonance spectroscopy for pancreatic cancer studies. Pancreas. 2012;41(3):474–80. doi:10.1097/MPA.0b013e31822a708c.CrossRefPubMed

38.

Harris DM, Li L, Chen M, Lagunero FT, Go VL, Boros LG. Diverse mechanisms of growth inhibition by luteolin, resveratrol, and quercetin in MIA PaCa-2 cells: a comparative glucose tracer study with the fatty acid synthase inhibitor C75. Metabolomics. 2012;8(2):201–10. doi:10.1007/s11306-011-0300-9.CrossRefPubMed

39.

Davis VW, Schiller DE, Eurich D, Bathe OF, Sawyer MB. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature. Ann Surg Oncol. 2013;20(Suppl 3):S415–23. doi:10.1245/s10434-012-2686-7.CrossRefPubMed

40.

Kobayashi T, Nishiumi S, Ikeda A, Yoshie T, Sakai A, Matsubara A, et al. A novel serum metabolomics-based diagnostic approach to pancreatic cancer. Cancer Epidemiol Biomark Prev. 2013;22(4):571–9. doi:10.1158/1055-9965.EPI-12-1033.CrossRef

41.

Leichtle AB, Ceglarek U, Weinert P, Nakas CT, Nuoffer JM, Kase J, et al. Pancreatic carcinoma, pancreatitis, and healthy controls: metabolite models in a three-class diagnostic dilemma. Metabolomics. 2013;9(3):677–87. doi:10.1007/s11306-012-0476-7.CrossRefPubMed

42.

Zhang G, He P, Tan H, Budhu A, Gaedcke J, Ghadimi BM, et al. Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer. Clin Cancer Res. 2013;19(18):4983–93. doi:10.1158/1078-0432.CCR-13-0209.CrossRefPubMedPubMedCentral

43.

Cantoria MJ, Boros LG, Meuillet EJ. Contextual inhibition of fatty acid synthesis by metformin involves glucose-derived acetyl-CoA and cholesterol in pancreatic tumor cells. Metabolomics. 2014;10(1):91–104. doi:10.1007/s11306-013-0555-4.CrossRefPubMed

44.

Fujiwara Y, Kobayashi T, Chayahara N, Imamura Y, Toyoda M, Kiyota N, et al. Metabolomics evaluation of serum markers for cachexia and their intra-day variation in patients with advanced pancreatic cancer. PLoS ONE. 2014;9(11):e113259. doi:10.1371/journal.pone.0113259.CrossRefPubMedPubMedCentral

45.

LaConti JJ, Laiakis EC, Mays AD, Peran I, Kim SE, Shay JW, et al. Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma. BMC Genom. 2015;16(Suppl 1):S1. doi:10.1186/1471-2164-16-S1-S1.CrossRef

46.

Fukutake N, Ueno M, Hiraoka N, Shimada K, Shiraishi K, Saruki N, et al. A novel multivariate index for pancreatic cancer detection based on the plasma free amino acid profile. PLoS ONE. 2015;10(7):e0132223. doi:10.1371/journal.pone.0132223.CrossRefPubMedPubMedCentral

47.

Sakai A, Suzuki M, Kobayashi T, Nishiumi S, Yamanaka K, Hirata Y, et al. Pancreatic cancer screening using a multiplatform human serum metabolomics system. Biomark Med. 2016;10(6):577–86. doi:10.2217/bmm-2016-0020.CrossRefPubMed

48.

Mayers JR, Wu C, Clish CB, Kraft P, Torrence ME, Fiske BP, et al. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med. 2014;20(10):1193–8. doi:10.1038/nm.3686.CrossRefPubMedPubMedCentral

49.

Szpetnar M, Matras P, Boguszewska-Czubara A, Kielczykowska M, Rudzki S, Musik I. Is additional enrichment of diet in branched-chain amino acids or glutamine beneficial for patients receiving total parenteral nutrition after gastrointestinal cancer surgery? Adv Clin Exp Med. 2014;23(3):423–31.CrossRefPubMed

Titel: Metabolomics in pancreatic cancer biomarkers research
verfasst von: Jaroslav Tumas
Kotryna Kvederaviciute
Marius Petrulionis
Benediktas Kurlinkus
Arnas Rimkus
Greta Sakalauskaite
Jonas Cicenas
Audrius Sileikis
Publikationsdatum: 01.12.2016
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 12/2016
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-016-0853-6

Springer Medizin

Metabolomics in pancreatic cancer biomarkers research

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2016

Generation of T cell effectors using tumor cell-loaded dendritic cells for adoptive T cell therapy

The prognostic implication of the expression of EGFR, p53, cyclin D1, Bcl-2 and p16 in primary locally advanced oral squamous cell carcinoma cases: a tissue microarray study

Lumbar-sacral bone marrow dose modeling for acute hematological toxicity in anal cancer patients treated with concurrent chemo-radiation

Tumor lysis syndrome and metastatic melanoma

Percutaneous image-guided cryoablation: current applications and results in the oncologic field

rs15869 at miRNA binding site in BRCA2 is associated with breast cancer susceptibility

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie